Publications

Zanidatamab

Categories
Search
Zanidatamab
June 4, 2022
ASCO
Zanidatamab, a HER2-targeted bispecific antibody, in combination with tislelizumab and chemotherapy as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma: Preliminary results from a Phase 1b/2 study
Zanidatamab
December 8, 2021
SABCS
Zanidatamab in Combination with Evorpacept in Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-expressing Cancers, Including Breast Cancer: a Phase 1b/2, Multicenter, Open-Label, Dose-Finding and Cohort-Expansion Study (ZWI-ZW25-204)
Hurvitz et al.
Zanidatamab
December 8, 2021
SABCS
Zanidatamab (ZW25), a HER2-targeted Bispecific Antibody, in Combination with Chemotherapy (chemo) for HER2-positive Breast Cancer (BC): Results from a Phase 1 Trial
Bedard et al.
Zanidatamab
September 15, 2021
ESMO
Phase (Ph) 2 Study of Zanidatamab + Chemotherapy (chemo) in First Line (1L) HER2 expressing Gastroesophageal Adenocarcinoma (GEA)
Ku et al.
Zanidatamab
April 10, 2021
AACR
Super-resolution imaging studies of zanidatamab: providing insights into its bispecific mode of action
Abraham et al.
Zanidatamab
April 10, 2021
AACR
The bispecific antibody zanidatamab’s (ZW25’s) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers
Weisser et al.
Zanidatamab
January 15, 2021
ASCO GI
A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers (BTCs)
Pant et al.
Zanidatamab
January 15, 2021
ASCO GI
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study
Meric-Bernstam et al.
Zanidatamab
January 15, 2021
ASCO GI
Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study
Meric-Bernstam et al.
Zanidatamab
November 22, 2019
ESMO Asia
Safety, Anti-Tumor Activity, and Biomarker Results of the HER2-Targeted Bispecific Antibody ZW25 in HER2-Expressing Solid Tumor
Oh et al.